David T. Rubin to Drug Administration Schedule
This is a "connection" page, showing publications David T. Rubin has written about Drug Administration Schedule.
Connection Strength
0.704
-
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020 03; 51(6):637-643.
Score: 0.158
-
Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
Score: 0.148
-
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
Score: 0.139
-
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. J Crohns Colitis. 2016 Aug; 10(8):925-33.
Score: 0.121
-
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
Score: 0.098
-
Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
Score: 0.024
-
Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide. Gastroenterology. 2005 Aug; 129(2):770-2.
Score: 0.015